The Australian Natural Therapeutics Group (ANTG) takes a holistic approach to the production of plant-based medicines. We cultivate and manufacture high-quality products, develop our own genetics, and are at the forefront of cutting edge research and development in Australia.

We are a dedicated team of industry experts, scientists, and business leaders, united in making a meaningful difference to people’s lives through our passion for the plant.

Quality & Purity
Our values are reflected in the words quality and purity, and guide us EVERY DAY.

From seed to shelf, we are committed to delivering consistent and high-quality results every time, meeting the highest possible standards. Our patients are at the centre of all we do. We listen and act with purity of intent, considering their needs, first.

our approach

We believe the development of optimal genetics is paramount.

Selective breeding has allowed us to create plant varieties rich in medicinal content, unique terpene profiles and yield quality.

Grounded in innovation, we invest hundreds of hours developing strain-specific plant-based medicine, unique to us.

ANTG is a leading producer of premium-grade plant-based medicines, using optimal genetics and best-practice cultivation.

In our state-of-the-art facilities across the country, we apply well-established horticultural methodology for consistent yield and quality.

As an Australian GMP-certified company, our entire production and manufacturing processes are independently verified to the highest pharmaceutical quality standards worldwide.

Our rigorous approach to quality assurance ensures our industry-leading products are highly controlled, and standardisation on processes and testing are both predictable and reproducible, two fundamental indicators of pharmaceutical quality.

ANTG’s R&D activities has two distinct functions: product development and clinical research.

With a focus on delivering multiple whole plant formats of the same strain, our R&D department is constantly innovating to ensure we develop a variety of products to suit the individual needs of our patients.

We see the advancement of scientific knowledge as the main driver of progress and change within the medicinal plant-based industry and wider community. As such, investing in clinical research is a fundamental part of our business model. The R&D department manages several research projects with our university partners from pre-clinical laboratory studies to large-scale human clinical trials. These are documented on our research page.

How we work

Founded on compassion, ANTG’s commitment to higher standards is at the forefront of all we do, from serving the community to investing in cutting-edge research.

Our purpose

Australian Natural Therapeutics Group (ANTG) was founded on the principles of care, quality, and compassion.

A focus on science

In this developing industry, the collection of scientific knowledge in the form of evidence, research and data is essential.

Cutting edge Research

Our focus on Research and Development aims to better understand the potential therapeutic value of plant-based medicine, and its interaction with biological systems.

Serving our community

Our mission is to enhance the well-being of our community.

Our purpose

Australian Natural Therapeutics Group (ANTG) was founded on the principles of care, quality, and compassion.

Our commitment to community, education, and research define our values-rich approach to holistic healthcare.

Our mission is to enhance and ensure the ongoing wellbeing of our community.

We are dedicated to higher standards.

A focus on science

In this developing industry, the collection of scientific knowledge in the form of evidence, research and data is essential.

Producing high quality plant-based medicine relies on agronomic efficiency and advanced production methods.

At ANTG our operations include:

Product development
The research and development function is at the forefront of product development and delivery technologies to ensure our products achieve the best patient outcomes.

Plant breeding and genetics
ANTG has a dedicated plant performance team to internally breed and develop new plant genetics to underpin our scientific research on patient care. Several years of cultivation research and development trials have gone toward identifying ideal environmental and nutritional requirements of our plants.

Certified GACP Standard
Our propagation and cultivation practices are independently certified to surpass Good Agricultural and Collection Practices standards ensuring the quality and purity of our agronomic processes and outputs.

Manufacturing and extraction
As an Australian GMP-certified company, our production and manufacturing processes are independently verified to the highest pharmaceutical quality standards worldwide.

Quality Assurance
Our rigorous approach to quality assurance ensures our products are highly controlled, and standardisation on processes and testing are both predictable and reproducible, two fundamental indicators of pharmaceutical quality.

Cutting edge Research

Our focus on Research and Development aims to better understand the potential therapeutic value of plant-based medicine, and its interaction with biological systems. We partner with leading scientists and Universities to develop clinically relevant evidence for the safe and effective use of cannabinoid therapy for Australian patients.

Investment in research is one of our proudest achievements. In 2017 ANTG partnered with biomedical scientist and cancer researcher Associate Professor Matt Dun, to investigate our one of our propriety plant-based medicines.

The team of scientists from Hunter Medical Research Institute (HMRI) at the University of Newcastle was seeking to expand their understanding of plant-based medicine in the prevention and treatment of diseases.

After almost two years of focused research examining the anti-cancer properties of out plant extract, they found one of our  plant varieties could kill cancer cells in vitro.

And the research continues to evolve. New research is investigating what makes cancer cells sensitive and normal cells not, whether it is clinically relevant, and whether a variety of cancers respond. Studies are progressing to test our plant extracts in animal models and if the results are encouraging, studies could progress to human clinical trials.

 

Serving our community

Our mission is to enhance the well-being of our community. Our social responsibility to healthcare professionals and patients is to provide education and evidence-informed research.

We are passionate about producing the highest quality plant-based medicine. We lead with our values, taking pride and care in all that we do, from best practice cultivation methods to meeting strict quality assurance standards.

We care about what happens in the community and safeguard patient care by ensuring we meet the highest standards in the practice of plant-based therapies. Each individual should have the opportunity to make an informed decision on what is best for them.

We support compassionate access of medicines for all Australians, leading advocacy efforts to establish a national federal government scheme, backed by industry.

OUR HISTORY

ANTG founded

  • Acquired Office of Drug Control (ODC) licensed cultivation facility in Armidale, NSW.
  • Acquired state licensed cultivation business in California.
  • Completed ODC licensed R&D and manufacturing facility in Pitt Town, NSW.
  • Acquired licensed hemp business in Gosford, NSW.
  • Launched Eve hemp oil in Australia.
  • Commenced University of Newcastle (UoN) cancer study.
  • Completed phase 1 build of GMP facilities at Armidale.
  • Obtained ODC licenses (R&D, manufacture and import).
  • Signed EU export contracts with CannaMedical.
  • Launched Eve USA brand.
  • Obtained CSIRO Innovation Connections grant.
  • US operations (Eve Farms) won several accolades, including High Times Cup 2018 Sonoma, Chalice Cup 2018 Los Angeles.
  • Obtained GMP accreditation at Armidale.
  • Secured plant breeder rights for plant variety
  • Registered medicines in the Australian Register of Therapeutic Goods (ARTG)
  • Commenced Western Sydney University (WSU) Alzheimer’s study agreement
  • Cultivated first commercial crops under GACP/GMP license with first crops passing TGO93 and TGO100 testing
  • US operations (Eve Farms) won High Times Cup 2019 Bay Area.
  • Launched domestic market products (4 flower products).
  • Secured 4 additional ARTG listings for Australian patients and 3 additional ARTG export-only listings.
  • Released first compassionate prescriptions to Australian patients.
  • Achieved first bulk domestic sales of flower and trim products.
  • Delivered first order to German distributor Cannamedical.
  • Obtained ODC bulk oil extraction permit.
  • Obtained TGA bulk oil production license.
  • Began supply and development of S4 and S8 oil products and begun WSU clinical trials.
  • Release Australia oil products for SAS-B patients for first time.
  • Launched new 1:1 flower strain in Australia and Europe in Q4.
  • Shipped first oil order to Luvo’s German distribution centre via Cann Group contract.
  • Commenced animal studies phase in UoN cancer trials.
  • Commenced S3 product road map for Blackmores and OTC oil production.
  • To make first export to New Zealand distributor NUBU.
  • Expansion of Armidale facility underway.

  • Exported oils to Europe for first time.
  • Launched three different whole-plant oil varieties
  • Launched our first Global Selects product
  • First NZ shipment of CBD flower to our distribution partner NUBU
  • First NZ shipment of various whole-plant medicines to our distribution partner NUBU
  • Completed the GMP expansion of the Armidale facility
Our people
WE ARE PROUD TO BE INVOLVED IN SHAPING THE FUTURE OF NATURAL MEDICINE.

Led by a board of skilled commercial leaders, our multidisciplinary team includes expert horticulturalists, scientific researchers and medical advisors. Motivated by the profound health benefits of plant-based therapies, we are passionate about improving the lives of our patients.

Matt Cantelo

Founder & Chief Executive Officer

Learn More

James Gaskell

Chief Operating Officer

Learn More

Max Taylor

Chief Financial Officer

Learn More

Rangi Faulder

Director of Plant Performance and Genetics

Learn More

Andrew Cormack

Executive General Manager of Manufacturing

Learn More

Jim Kennard

Board Member

Learn More

Jarrad Dale

Special Projects

Learn More

Justin Sinclair

Chief Scientific Officer

Learn More

Beatriz Garabelli

Executive General Manager, Commercial

Learn More

Steve Bowne

Head of Sales

Learn More

Helen Kapalos

Head of Communications & Community

Learn More

Matthew Dewar

General Manager, Products and Portfolio

Learn More

Jim Cameron

Site General Manager

Learn More

Greg Dong

Financial Controller

Learn More

Resham Tolani

Medical Science Liaison

Learn More

Suzanne Roberts

Medical Science Liaison

Learn More

Daniel Harris

Medical Science Liaison

Learn More

Diane Forbes

Medical Science Liaison

Learn More

Our credentials

  • Good Manufacturing Practices (GMP)
  • Good Agricultural & Collection Practices (GACP)
  • Australian Grown
  • Australian Made

Export Licence

GMP Licence

Hemp DPI Licence

Import Licence

ODC Permit For Cultivation, Production And Manufacturing

ODC Licence

TGA Medicinal Cannabis Manufacturing Permit

NSW Health S4 Wholesale Licence – Distribution

NSW Health S8 Wholesale Licence – Distribution

NSW Health S8 Wholesale Licence – Manufacture

QLD Health Wholesale Indent Licence